BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 2014; 20(42): 15750-15755 [PMID: 25400459 DOI: 10.3748/wjg.v20.i42.15750]
URL: https://www.wjgnet.com/1007-9327/full/v20/i42/15750.htm
Number Citing Articles
1
Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu. Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studiesMedicine 2022; 101(49): e31799 doi: 10.1097/MD.0000000000031799
2
Maja Cigrovski Berkovic, Francesco Giovanardi, Anna Mrzljak, Quirino Lai. Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysisWorld Journal of Diabetes 2023; 14(8): 1289-1300 doi: 10.4239/wjd.v14.i8.1289
3
Shereen El Shorbagy, Fouad abuTaleb, Hany A. Labib, Huda Ebian, Ola A. Harb, Mona Saeed Mohammed, Hanaa A. Rashied, Khaled A. Elbana, Rasha Haggag. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib CombinationJournal of Gastrointestinal Cancer 2021; 52(1): 269 doi: 10.1007/s12029-020-00389-w
4
Miao-Ling Chen, Chun-Xue Wu, Jian-Bo Zhang, Hao Zhang, Yuan-Dong Sun, Shi-Lin Tian, Jian-Jun Han. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetesFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.996228
5
Sofia de Oliveira, Ruth A. Houseright, Alyssa L. Graves, Netta Golenberg, Benjamin G. Korte, Veronika Miskolci, Anna Huttenlocher. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafishJournal of Hepatology 2019; 70(4): 710 doi: 10.1016/j.jhep.2018.11.034
6
Aparna Bhat, Giada Sebastiani, Mamatha Bhat. Systematic review: Preventive and therapeutic applications of metformin in liver diseaseWorld Journal of Hepatology 2015; 7(12): 1652-1659 doi: 10.4254/wjh.v7.i12.1652
7
Alexandra I Thompson, Kylie P Conroy, Neil C Henderson. Hepatic stellate cells: central modulators of hepatic carcinogenesisBMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0291-5
8
Lena Schulte, Bernhard Scheiner, Torsten Voigtländer, Sandra Koch, Nora Schweitzer, Silke Marhenke, Philipp Ivanyi, Michael P. Manns, Thomas Rodt, Jan B. Hinrichs, Arndt Weinmann, Matthias Pinter, Arndt Vogel, Martha M. Kirstein. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinomaLiver International 2019; 39(4): 714 doi: 10.1111/liv.14048
9
Laurentia Gales, Leyla Forsea, Diana Mitrea, Irina Stefanica, Irina Stanculescu, Radu Mitrica, Mihai Georgescu, Oana Trifanescu, Rodica Anghel, Luiza Serbanescu. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer TherapyMedicina 2022; 58(9): 1239 doi: 10.3390/medicina58091239
10
Stephen Safe, Vijayalekshmi Nair, Keshav Karki. Metformin-induced anticancer activities: recent insightsBiological Chemistry 2018; 399(4): 321 doi: 10.1515/hsz-2017-0271
11
Ulfa Kholili, Alvin Hartanto Kurniawan, Choirina Winda, Ummi Maimunah, Poernomo Budi Setiawan. The Role of Metformin as Chemopreventive Strategies for Hepatocellular CarcinomaResearch Journal of Pharmacy and Technology 2023; : 377 doi: 10.52711/0974-360X.2023.00065
12
Yun‐Shan Wang, Lutao Du, Xingsi Liang, Peng Meng, Lei Bi, Yu‐li Wang, Chuanxin Wang, Bo Tang. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine‐Monophosphate–Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in MiceHepatology 2019; 69(4): 1614 doi: 10.1002/hep.30421
13
Woo Jin Jung, Sangmi Jang, Won Joon Choi, Jaewon Park, Gwang Hyeon Choi, Eun Sun Jang, Sook-Hyang Jeong, Won Seok Choi, Jae Hwan Lee, Chang Jin Yoon, Jin-Wook Kim. Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patientsScientific Reports 2022; 12(1) doi: 10.1038/s41598-022-18341-2
14
Young-Seok Seo, Yun-Jung Kim, Mi-Sook Kim, Kyung-Suk Suh, Sang Bum Kim, Chul Ju Han, Youn Joo Kim, Won Il Jang, Shin Hee Kang, Ha Jin Tchoe, Chan Mi Park, Ae Jung Jo, Hyo Jeong Kim, Jin A Choi, Hyung Jin Choi, Michael N. Polak, Min Jung Ko. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative ResectionMedicine 2016; 95(17): e3527 doi: 10.1097/MD.0000000000003527
15
Jian Zhou, Yang Ke, Xuefen Lei, Tiangen Wu, Yuehua Li, Tianhao Bao, Haoran Tang, Cheng Zhang, Xuesong Wu, Ge Wang, Jinze Li, Heng Zhang, Fan Ni, Zhengchen Ye, Lin Wang. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetesAnnals of Hepatology 2020; 19(3): 320 doi: 10.1016/j.aohep.2019.11.008
16
Xue Jiang, Hor-Yue Tan, Shanshan Teng, Yau-Tuen Chan, Di Wang, Ning Wang. The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular CarcinomaCancers 2019; 11(5): 647 doi: 10.3390/cancers11050647
17
Kaizhen Wang, Kuojun Zhang, Xiangyu Zhang, Dong Chen, Sheng Jiang. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC)Mini-Reviews in Medicinal Chemistry 2023; 23(11): 1154 doi: 10.2174/1389557522666220623150717
18
Jonathan M. Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F. Cobbold, Jeremy W. Tomlinson. Non-alcoholic fatty liver disease and diabetesMetabolism 2016; 65(8): 1096 doi: 10.1016/j.metabol.2016.01.001
19
Samuel O. Antwi, Zhuo Li, Kabir Mody, Lewis R. Roberts, Tushar Patel. Independent and Joint Use of Statins and Metformin by Elderly Patients With Diabetes and Overall Survival Following HCC DiagnosisJournal of Clinical Gastroenterology 2020; 54(5): 468 doi: 10.1097/MCG.0000000000001182
20
Thanida Tangjarusritaratorn, Watip Tangjittipokin, Tada Kunavisarut. Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without MetforminDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 1563 doi: 10.2147/DMSO.S295753
21
Xun Cao, Yaopan Wu, Jing Wang, Kuiyuan Liu, Xin Wang. The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysisJNCI Cancer Spectrum 2017; 1(1) doi: 10.1093/jncics/pkx007
22
Christian Labenz, Vera Prenosil, Sandra Koch, Yvonne Huber, Jens U. Marquardt, Jörn M. Schattenberg, Peter R. Galle, Arndt Weinmann, Marcus-Alexander Wörns. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibDigestive Diseases 2018; 36(1): 78 doi: 10.1159/000477578
23
Cui-Song Luo, Yun Lin, Wei-Ping Zhou, Jun Shi. Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysisEuropean Journal of Gastroenterology & Hepatology 2020; 32(8): 1030 doi: 10.1097/MEG.0000000000001610
24
Wei-Ru Cho, Chih-Chi Wang, Meng-Yun Tsai, Chen-Kai Chou, Yueh-Wei Liu, Yi-Ju Wu, Ming-Tsung Lin, Kuang-Den Chen, Ching-Hui Chuang, Pao-Yuan Huang, Tsung-Hui Hu, Ming-Chao Tsai, Ming-Lung Yu. Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patientsPLOS ONE 2021; 16(3): e0247231 doi: 10.1371/journal.pone.0247231
25
Rania Harati, Marc Vandamme, Benoit Blanchet, Christophe Bardin, Françoise Praz, Rifat Akram Hamoudi, Christèle Desbois-Mouthon. Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma CellsMolecular Pharmacology 2021; 100(1): 32 doi: 10.1124/molpharm.120.000223
26
Shu-Juan Ma, Yi-Xiang Zheng, Peng-Cheng Zhou, Yan-Ni Xiao, Hong-Zhuan Tan. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysisOncotarget 2016; 7(40): 66202 doi: 10.18632/oncotarget.11033
27
Maria Corina Plaz Torres, Ariel Jaffe, Rachel Perry, Elisa Marabotto, Mario Strazzabosco, Edoardo G. Giannini. Diabetes medications and risk of HCCHepatology 2022; 76(6): 1880 doi: 10.1002/hep.32439
28
Stephanie Talamantes, Michela Lisjak, Eduardo H. Gilglioni, Camilo J. Llamoza-Torres, Bruno Ramos-Molina, Esteban N. Gurzov. Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinomaJHEP Reports 2023; 5(9): 100811 doi: 10.1016/j.jhepr.2023.100811